Positive results of a study into the effects of an add-on to antipsychotics for the management of treatment-resistant schizophrenia (TRS) have been announced by Newron Pharmaceuticals.
Oxford Cannabinoid Technologies Holdings plc (OCTP), the pharmaceutical company developing prescription cannabinoid medicines, has announced that all cohorts have been dosed in a phase 1 study of OCT461201.
Complete clinical trials solution company, Hawthorne Effect, announced today (October 10) it had successfully recruited more than 1,000 patients in 48 states plus Hawaii for a study to qualify the prevalence of valvular heart disease (VHD).
A new patient-first service that will support sponsors and sites accelerate the development of their therapies has been launched by Innovative Trials yesterday (October 9).
CymaBay announced recently the initiation of its 52-week, placebo-controlled, randomized, phase 3 study — 'Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase (ALP) Levels in subjects with Primary Biliary Cholangitis...
A drug that has the ability to ‘transform the landscape’ for people living with metastatic colorectal cancer (CRC) has been granted priority review by the US Food and Drug Administration (FDA).
Mutation in the progranulin (GRN) gene is just one of several hereditary factors that can cause frontotemporal dementia, a rare and rapidly progressive neurodegenerative disease.
Altasciences is expanding its facility in Columbia, Missouri to provide bioanalytical services in support of preclinical and clinical studies conducted in the US.
Phesi launches an AI-powered SaaS solution to mitigate potential costly delays through a search and select investigator function to determine trial sites for clinical studies.
Catalent’s existing clinical packaging facility in Shanghai is nearing the end of its expansion, ready to meet the needs of the growing Asia-Pacific region.
Zimmer Biomet has tapped Apple and created an app to facilitate patient and treatment team connection as part of a clinical study that aims to enroll as many as 10,000 participants.